Active Ingredient(s): Umbralisib Tosylate
FDA Approved: * February 5, 2021
Pharm Company: * TG THERAPS
Category: Cancer

Umbralisib, sold under the brand name Ukoniq, is a medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL).[2] It is taken by mouth.[2] The most common side effects include increased creatinine, diarrhea-colitis, fatigue, nausea, neutropenia, transaminase elevation, musculoskeletal pain, anemia, thrombocytopenia, upper respiratory tract infection, vomiting, abdominal pain, decreased appetite, and rash.[2] Umbral... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Ukoniq 260.2 mg Oral Tablet, Film Coated
NDC: 73150-200
Tg Therapeutics, Inc.